Current Protein Identity：P07700
New Search
Difference tags compare only the current result set; every original PDB and assembly record remains separate.
Related-Structure Differences
Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.
| PDB Entry | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Experimental Method | Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1DEP MEMBRANE PROTEIN, NMR, 1 STRUCTURE Deposited 1995-08-23 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
345–359（15 aa）
|
Not recorded | No recorded non-water small molecule | SOLUTION NMR | mmCIF provides none of the parsed conditions | Resolution not provided |
| 2VT4 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND CYANOPINDOLOL Deposited 2008-05-09 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain A
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain A
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES | P32 Cyanopindolol × 2 NA SODIUM ION × 2 SOG octyl 1-thio-beta-D-glucopyranoside × 6 D10 DECANE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.1；VAPOUR DIFFUSION. EQUAL VOLUMES OF PROTEIN (6MG/ML) IN 10MM TRIS-HCL PH7.7, 50MM NACL, 0.1MM EDTA, 0.35% OCTYLTHIOGLUCOSIDE, 0.5MM CYANOPINDOLOL AND RESERVOIR 0.1M ADA, PH 6.9-7.3, 29-32% PEG600.
|
Resolution 2.70 Å R-free 0.268 |
| 2VT4 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND CYANOPINDOLOL Deposited 2008-05-09 | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain C
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain C
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain C
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain D
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain D
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain D
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES | P32 Cyanopindolol × 2 NA SODIUM ION × 2 SOG octyl 1-thio-beta-D-glucopyranoside × 6 D10 DECANE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.1；VAPOUR DIFFUSION. EQUAL VOLUMES OF PROTEIN (6MG/ML) IN 10MM TRIS-HCL PH7.7, 50MM NACL, 0.1MM EDTA, 0.35% OCTYLTHIOGLUCOSIDE, 0.5MM CYANOPINDOLOL AND RESERVOIR 0.1M ADA, PH 6.9-7.3, 29-32% PEG600.
|
Resolution 2.70 Å R-free 0.268 |
| 2VT4 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND CYANOPINDOLOL Deposited 2008-05-09 | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain A
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain A
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES | P32 Cyanopindolol × 1 NA SODIUM ION × 1 SOG octyl 1-thio-beta-D-glucopyranoside × 3 D10 DECANE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.1；VAPOUR DIFFUSION. EQUAL VOLUMES OF PROTEIN (6MG/ML) IN 10MM TRIS-HCL PH7.7, 50MM NACL, 0.1MM EDTA, 0.35% OCTYLTHIOGLUCOSIDE, 0.5MM CYANOPINDOLOL AND RESERVOIR 0.1M ADA, PH 6.9-7.3, 29-32% PEG600.
|
Resolution 2.70 Å R-free 0.268 |
| 2VT4 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND CYANOPINDOLOL Deposited 2008-05-09 | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES | P32 Cyanopindolol × 1 NA SODIUM ION × 1 SOG octyl 1-thio-beta-D-glucopyranoside × 3 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.1；VAPOUR DIFFUSION. EQUAL VOLUMES OF PROTEIN (6MG/ML) IN 10MM TRIS-HCL PH7.7, 50MM NACL, 0.1MM EDTA, 0.35% OCTYLTHIOGLUCOSIDE, 0.5MM CYANOPINDOLOL AND RESERVOIR 0.1M ADA, PH 6.9-7.3, 29-32% PEG600.
|
Resolution 2.70 Å R-free 0.268 |
| 2VT4 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND CYANOPINDOLOL Deposited 2008-05-09 | Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain C
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain C
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain C
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES | P32 Cyanopindolol × 1 NA SODIUM ION × 1 SOG octyl 1-thio-beta-D-glucopyranoside × 3 D10 DECANE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.1；VAPOUR DIFFUSION. EQUAL VOLUMES OF PROTEIN (6MG/ML) IN 10MM TRIS-HCL PH7.7, 50MM NACL, 0.1MM EDTA, 0.35% OCTYLTHIOGLUCOSIDE, 0.5MM CYANOPINDOLOL AND RESERVOIR 0.1M ADA, PH 6.9-7.3, 29-32% PEG600.
|
Resolution 2.70 Å R-free 0.268 |
| 2VT4 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND CYANOPINDOLOL Deposited 2008-05-09 | Assembly 6 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain D
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain D
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain D
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES | P32 Cyanopindolol × 1 NA SODIUM ION × 1 SOG octyl 1-thio-beta-D-glucopyranoside × 3 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.1；VAPOUR DIFFUSION. EQUAL VOLUMES OF PROTEIN (6MG/ML) IN 10MM TRIS-HCL PH7.7, 50MM NACL, 0.1MM EDTA, 0.35% OCTYLTHIOGLUCOSIDE, 0.5MM CYANOPINDOLOL AND RESERVOIR 0.1M ADA, PH 6.9-7.3, 29-32% PEG600.
|
Resolution 2.70 Å R-free 0.268 |
| 2Y00 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB92) Deposited 2010-11-30 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 5 Y00 DOBUTAMINE × 1 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (14.5MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, S)-DOBUTAMINE, 1.3MG/ML CHS, 0.55% HEGA-10, 0.1M TRIS-HCL PH8.5, 25% PEG600 AT 4 DEGREES C
|
Resolution 2.50 Å R-free 0.256 |
| 2Y00 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB92) Deposited 2010-11-30 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 5 Y00 DOBUTAMINE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (14.5MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, S)-DOBUTAMINE, 1.3MG/ML CHS, 0.55% HEGA-10, 0.1M TRIS-HCL PH8.5, 25% PEG600 AT 4 DEGREES C
|
Resolution 2.50 Å R-free 0.256 |
| 2Y00 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB92) Deposited 2010-11-30 | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-368
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 4 2CV HEGA-10 × 10 Y00 DOBUTAMINE × 2 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (14.5MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, S)-DOBUTAMINE, 1.3MG/ML CHS, 0.55% HEGA-10, 0.1M TRIS-HCL PH8.5, 25% PEG600 AT 4 DEGREES C
|
Resolution 2.50 Å R-free 0.256 |
| 2Y01 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB102) Deposited 2010-11-30 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 5 Y00 DOBUTAMINE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (15MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, S)-DOBUTAMINE, 0.9MG/ML CHS, 0.6% HEGA-10, 0.1M BICINE PH9, 25% PEG600 AT 4 DEGREES C, pH 9.0
|
Resolution 2.60 Å R-free 0.266 |
| 2Y01 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB102) Deposited 2010-11-30 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 5 Y00 DOBUTAMINE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (15MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, S)-DOBUTAMINE, 0.9MG/ML CHS, 0.6% HEGA-10, 0.1M BICINE PH9, 25% PEG600 AT 4 DEGREES C, pH 9.0
|
Resolution 2.60 Å R-free 0.266 |
| 2Y01 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST DOBUTAMINE (CRYSTAL DOB102) Deposited 2010-11-30 | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-368
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 4 2CV HEGA-10 × 10 Y00 DOBUTAMINE × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (15MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, S)-DOBUTAMINE, 0.9MG/ML CHS, 0.6% HEGA-10, 0.1M BICINE PH9, 25% PEG600 AT 4 DEGREES C, pH 9.0
|
Resolution 2.60 Å R-free 0.266 |
| 2Y02 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST CARMOTEROL Deposited 2010-11-30 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 5 WHJ CARMOTEROL × 1 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (16MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, R)-CARMOTEROL, 1.9MG/ML CHS, 0.65% HEGA-10, 0.1M BICINE PH9.0, 26% PEG600 AT 4 DEGREES C
|
Resolution 2.60 Å R-free 0.268 |
| 2Y02 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST CARMOTEROL Deposited 2010-11-30 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 5 WHJ CARMOTEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (16MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, R)-CARMOTEROL, 1.9MG/ML CHS, 0.65% HEGA-10, 0.1M BICINE PH9.0, 26% PEG600 AT 4 DEGREES C
|
Resolution 2.60 Å R-free 0.268 |
| 2Y02 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST CARMOTEROL Deposited 2010-11-30 | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-368
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 4 2CV HEGA-10 × 10 WHJ CARMOTEROL × 2 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (16MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, R)-CARMOTEROL, 1.9MG/ML CHS, 0.65% HEGA-10, 0.1M BICINE PH9.0, 26% PEG600 AT 4 DEGREES C
|
Resolution 2.60 Å R-free 0.268 |
| 2Y03 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST ISOPRENALINE Deposited 2010-11-30 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 1 2CV HEGA-10 × 3 5FW ISOPRENALINE × 1 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (15MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R)-ISOPRENALINE, 0.45MG/ML CHS, 0.5% HEGA-10, 0.1M TRIS-HCL PH8.5, 28% PEG600 AT 4 DEGREES C
|
Resolution 2.85 Å R-free 0.254 |
| 2Y03 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST ISOPRENALINE Deposited 2010-11-30 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 1 2CV HEGA-10 × 3 5FW ISOPRENALINE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (15MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R)-ISOPRENALINE, 0.45MG/ML CHS, 0.5% HEGA-10, 0.1M TRIS-HCL PH8.5, 28% PEG600 AT 4 DEGREES C
|
Resolution 2.85 Å R-free 0.254 |
| 2Y03 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND AGONIST ISOPRENALINE Deposited 2010-11-30 | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-368
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 6 5FW ISOPRENALINE × 2 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (15MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R)-ISOPRENALINE, 0.45MG/ML CHS, 0.5% HEGA-10, 0.1M TRIS-HCL PH8.5, 28% PEG600 AT 4 DEGREES C
|
Resolution 2.85 Å R-free 0.254 |
| 2Y04 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST SALBUTAMOL Deposited 2010-11-30 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 5 68H SALBUTAMOL × 1 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (16.5MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, S)-SALBUTAMOL, 1.0MG/ML CHS, 0.5% HEGA-10, 0.1M BICINE PH9.0, 28% PEG400 AT 4 DEGREES C
|
Resolution 3.05 Å R-free 0.255 |
| 2Y04 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST SALBUTAMOL Deposited 2010-11-30 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 5 68H SALBUTAMOL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (16.5MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, S)-SALBUTAMOL, 1.0MG/ML CHS, 0.5% HEGA-10, 0.1M BICINE PH9.0, 28% PEG400 AT 4 DEGREES C
|
Resolution 3.05 Å R-free 0.255 |
| 2Y04 TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND PARTIAL AGONIST SALBUTAMOL Deposited 2010-11-30 | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-368
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-368
|
Mutation：YES Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 4 2CV HEGA-10 × 10 68H SALBUTAMOL × 2 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；SITTING DROP VAPOUR DIFFUSION, PROTEIN (16.5MG/ML) IN 100MM NACL, 0.1MM EDTA, 1.0MM (R, S)-SALBUTAMOL, 1.0MG/ML CHS, 0.5% HEGA-10, 0.1M BICINE PH9.0, 28% PEG400 AT 4 DEGREES C
|
Resolution 3.05 Å R-free 0.255 |
| 2YCW TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CARAZOLOL Deposited 2011-03-17 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain A
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain A
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES | CAU (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol × 1 2CV HEGA-10 × 2 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 8.1；pH 8.1
|
Resolution 3.00 Å R-free 0.295 |
| 2YCW TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CARAZOLOL Deposited 2011-03-17 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES | CAU (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol × 1 2CV HEGA-10 × 3 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 8.1；pH 8.1
|
Resolution 3.00 Å R-free 0.295 |
| 2YCX TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CYANOPINDOLOL Deposited 2011-03-17 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–367（335 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES | P32 Cyanopindolol × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 7.3；pH 7.3
|
Resolution 3.25 Å R-free 0.325 |
| 2YCX TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CYANOPINDOLOL Deposited 2011-03-17 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–367（335 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES | P32 Cyanopindolol × 1 SOG octyl 1-thio-beta-D-glucopyranoside × 3 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 7.3；pH 7.3
|
Resolution 3.25 Å R-free 0.325 |
| 2YCY TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CYANOPINDOLOL Deposited 2011-03-17 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain A
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain A
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES | P32 Cyanopindolol × 1 SOG octyl 1-thio-beta-D-glucopyranoside × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 7.2；pH 7.2
|
Resolution 3.15 Å R-free 0.292 |
| 2YCY TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST CYANOPINDOLOL Deposited 2011-03-17 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES | P32 Cyanopindolol × 1 SOG octyl 1-thio-beta-D-glucopyranoside × 3 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 7.2；pH 7.2
|
Resolution 3.15 Å R-free 0.292 |
| 2YCZ TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST IODOCYANOPINDOLOL Deposited 2011-03-17 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain A
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain A
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES | I32 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3-iodo-1H-indole-2-carbonitrile × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 7；pH 7.0
|
Resolution 3.65 Å R-free 0.270 |
| 2YCZ TURKEY BETA1 ADRENERGIC RECEPTOR WITH STABILISING MUTATIONS AND BOUND ANTAGONIST IODOCYANOPINDOLOL Deposited 2011-03-17 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–243（211 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
272–276（5 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
279–367（89 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：YES Mutation：YES Mutation：YES | I32 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3-iodo-1H-indole-2-carbonitrile × 1 SOG octyl 1-thio-beta-D-glucopyranoside × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 7；pH 7.0
|
Resolution 3.65 Å R-free 0.270 |
| 3ZPQ Thermostabilised turkey beta1 adrenergic receptor with 4-(piperazin-1- yl)-1H-indole bound (compound 19) Deposited 2013-03-01 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–243（211 aa）
Fragment：RESIDUES 33-243,272-368
Chain A
272–368（97 aa）
Fragment：RESIDUES 33-243,272-368
|
Mutation：YES Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 4 XF5 4-(PIPERAZIN-1-YL)-1H-INDOLE × 1 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 9；277 K；0.1M BICINE PH9.0, 24% PEG600, 4C
|
Resolution 2.80 Å R-free 0.274 |
| 3ZPQ Thermostabilised turkey beta1 adrenergic receptor with 4-(piperazin-1- yl)-1H-indole bound (compound 19) Deposited 2013-03-01 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–243（211 aa）
Fragment：RESIDUES 33-243,272-368
Chain B
272–368（97 aa）
Fragment：RESIDUES 33-243,272-368
|
Mutation：YES Mutation：YES | Y01 CHOLESTEROL HEMISUCCINATE × 2 2CV HEGA-10 × 5 XF5 4-(PIPERAZIN-1-YL)-1H-INDOLE × 1 NA SODIUM ION × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 9；277 K；0.1M BICINE PH9.0, 24% PEG600, 4C
|
Resolution 2.80 Å R-free 0.274 |
| 3ZPR Thermostabilised turkey beta1 adrenergic receptor with 4-methyl-2-(piperazin-1-yl) quinoline bound Deposited 2013-03-01 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–243（211 aa）
Fragment：RESIDUES 33-243,272-368
Chain A
272–368（97 aa）
Fragment：RESIDUES 33-243,272-368
|
Mutation：YES Mutation：YES | NA SODIUM ION × 2 Y01 CHOLESTEROL HEMISUCCINATE × 2 3WC 4-METHYL-2-(PIPERAZIN-1-YL) QUINOLINE × 1 2CV HEGA-10 × 3 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 9；277 K；0.1M BICINE PH9.0, 24% PEG600, 4C
|
Resolution 2.70 Å R-free 0.266 |
| 3ZPR Thermostabilised turkey beta1 adrenergic receptor with 4-methyl-2-(piperazin-1-yl) quinoline bound Deposited 2013-03-01 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–243（211 aa）
Fragment：RESIDUES 33-243,272-368
Chain B
272–368（97 aa）
Fragment：RESIDUES 33-243,272-368
|
Mutation：YES Mutation：YES | NA SODIUM ION × 2 Y01 CHOLESTEROL HEMISUCCINATE × 2 3WC 4-METHYL-2-(PIPERAZIN-1-YL) QUINOLINE × 1 2CV HEGA-10 × 5 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 9；277 K；0.1M BICINE PH9.0, 24% PEG600, 4C
|
Resolution 2.70 Å R-free 0.266 |
| 4AMI Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist bucindolol Deposited 2012-03-11 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–243（211 aa）
Fragment：RESIDUES 33-243,272-368
Chain A
272–368（97 aa）
Fragment：RESIDUES 33-243,272-368
|
Mutation：YES Mutation：YES | G90 2-[(2S)-3-[[1-(1H-indol-3-yl)-2-methyl-propan-2-yl]amino]-2-oxidanyl-propoxy]benzenecarbonitrile × 1 2CV HEGA-10 × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 9；277 K；0.1 M BICINE PH 9.0, 22% PEG 600, 4 DEGREES CELSIUS.
|
Resolution 3.20 Å R-free 0.279 |
| 4AMI Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist bucindolol Deposited 2012-03-11 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–243（211 aa）
Fragment：RESIDUES 33-243,272-368
Chain B
272–368（97 aa）
Fragment：RESIDUES 33-243,272-368
|
Mutation：YES Mutation：YES | G90 2-[(2S)-3-[[1-(1H-indol-3-yl)-2-methyl-propan-2-yl]amino]-2-oxidanyl-propoxy]benzenecarbonitrile × 1 2CV HEGA-10 × 4 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 9；277 K；0.1 M BICINE PH 9.0, 22% PEG 600, 4 DEGREES CELSIUS.
|
Resolution 3.20 Å R-free 0.279 |
| 4AMJ Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist carvedilol Deposited 2012-03-12 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–243（211 aa）
Fragment：RESIDUES 33-243,272-368
Chain A
272–368（97 aa）
Fragment：RESIDUES 33-243,272-368
|
Mutation：YES Mutation：YES | CVD (2S)-1-(8H-CARBAZOL-4-YLOXY)-3-[2-(2-METHOXYPHENOXY)ETHYLAMINO]PROPAN-2-OL × 1 NA SODIUM ION × 1 2CV HEGA-10 × 8 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 9；277 K；0.1 M BICINE PH 9.0, 22% PEG 600, 4 DEGREES CELSIUS.
|
Resolution 2.30 Å R-free 0.240 |
| 4AMJ Turkey beta1 adrenergic receptor with stabilising mutations and bound biased agonist carvedilol Deposited 2012-03-12 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–243（211 aa）
Fragment：RESIDUES 33-243,272-368
Chain B
272–368（97 aa）
Fragment：RESIDUES 33-243,272-368
|
Mutation：YES Mutation：YES | CVD (2S)-1-(8H-CARBAZOL-4-YLOXY)-3-[2-(2-METHOXYPHENOXY)ETHYLAMINO]PROPAN-2-OL × 1 NA SODIUM ION × 1 2CV HEGA-10 × 4 | X-RAY DIFFRACTION |
X-ray crystallization conditions
pH 9；277 K；0.1 M BICINE PH 9.0, 22% PEG 600, 4 DEGREES CELSIUS.
|
Resolution 2.30 Å R-free 0.240 |
| 4BVN Ultra-thermostable beta1-adrenoceptor with cyanopindolol bound Deposited 2013-06-26 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–243（211 aa）
Chain A
272–368（97 aa）
|
Mutation：YES Mutation：YES | NA SODIUM ION × 2 P32 Cyanopindolol × 1 MHA (CARBAMOYLMETHYL-CARBOXYMETHYL-AMINO)-ACETIC ACID × 1 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7 | X-RAY DIFFRACTION |
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293 K；25% PEG 600, 0.1M ADA PH7.0 LIPID CUBIC PHASE (LCP) TEMPERATURE 293K
|
Resolution 2.10 Å R-free 0.246 |
| 4GPO Oligomeic Turkey Beta1-Adrenergic G Protein-Coupled Receptor Deposited 2012-08-21 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
31–368（338 aa）
Fragment：RESIDUES 33-243,272-276,279-367
Chain B
31–368（338 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：STABILISING MUTATIONS Mutation：STABILISING MUTATIONS | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；20mM sodium acetate, 100-300mM ammonium sulfate, 26~30% PEG200, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 3.50 Å R-free 0.355 |
| 5A8E thermostabilised beta1-adrenoceptor with rationally designed inverse agonist 7-methylcyanopindolol bound Deposited 2015-07-15 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–368（336 aa）
|
Mutation：YES | NA SODIUM ION × 2 XTK 4-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]-7-methyl-1H-indole-2-carbonitrile × 1 MHA (CARBAMOYLMETHYL-CARBOXYMETHYL-AMINO)-ACETIC ACID × 1 OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 5 | X-RAY DIFFRACTION |
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293 K；25% PEG600, 0.1M ADA PH7.0, LIPIDIC CUBIC PHASE (LCP), TEMPERATURE 293K
|
Resolution 2.40 Å R-free 0.248 |
| 5F8U Ligand occupancy in crystal structure of beta1-adrenergic receptor previously submitted by Huang et al Deposited 2015-12-09 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
33–368（336 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：R68S,M90V,Y227A,A282L,F327A,F338MC116L, C358A | P32 Cyanopindolol × 1 | X-RAY DIFFRACTION | mmCIF provides none of the parsed conditions | Resolution 3.35 Å R-free 0.382 |
| 5F8U Ligand occupancy in crystal structure of beta1-adrenergic receptor previously submitted by Huang et al Deposited 2015-12-09 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
33–368（336 aa）
Fragment：RESIDUES 33-243,272-276,279-367
|
Mutation：R68S,M90V,Y227A,A282L,F327A,F338MC116L, C358A | P32 Cyanopindolol × 1 | X-RAY DIFFRACTION | mmCIF provides none of the parsed conditions | Resolution 3.35 Å R-free 0.382 |
| 6H7J ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND AGONIST ISOPRENALINE AND NANOBODY Nb80 Deposited 2018-07-31 | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain A
44–368（325 aa）
|
Mutation：R68S,M90V,C116L,F327A,F338M,C358A | 5FW ISOPRENALINE × 1 NA SODIUM ION × 1 2CV HEGA-10 × 3 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.80 Å R-free 0.317 |
| 6H7J ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND AGONIST ISOPRENALINE AND NANOBODY Nb80 Deposited 2018-07-31 | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain B
44–368（325 aa）
|
Mutation：R68S,M90V,C116L,F327A,F338M,C358A | 5FW ISOPRENALINE × 1 NA SODIUM ION × 1 2CV HEGA-10 × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.80 Å R-free 0.317 |
| 6H7L ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST DOBUTAMINE AND NANOBODY Nb6B9 Deposited 2018-07-31 | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain A
44–368（325 aa）
|
Mutation：R68S,M90V,C116L,F327A,F338M,C358A | 2CV HEGA-10 × 6 NA SODIUM ION × 1 Y00 DOBUTAMINE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.70 Å R-free 0.278 |
| 6H7L ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST DOBUTAMINE AND NANOBODY Nb6B9 Deposited 2018-07-31 | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain B
44–368（325 aa）
|
Mutation：R68S,M90V,C116L,F327A,F338M,C358A | 2CV HEGA-10 × 3 NA SODIUM ION × 1 Y00 DOBUTAMINE × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.70 Å R-free 0.278 |
| 6H7M ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST SALBUTAMOL AND NANOBODY Nb6B9 Deposited 2018-07-31 | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain A
44–368（325 aa）
|
Mutation：R68S,M90V,C116L,F327A,F338M,C358A | 2CV HEGA-10 × 3 68H SALBUTAMOL × 1 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.76 Å R-free 0.285 |
| 6H7M ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST SALBUTAMOL AND NANOBODY Nb6B9 Deposited 2018-07-31 | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain B
44–368（325 aa）
|
Mutation：R68S,M90V,C116L,F327A,F338M,C358A | 2CV HEGA-10 × 4 68H SALBUTAMOL × 1 NA SODIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.76 Å R-free 0.285 |
| 6H7N ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST XAMOTEROL AND NANOBODY Nb6B9 Deposited 2018-07-31 | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain A
44–368（325 aa）
|
Mutation：R68S,M90V,C116L,F327A,F338M,C358A | FVK ~{N}-[2-[[(2~{S})-2-oxidanyl-3-(4-oxidanylphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide × 1 NA SODIUM ION × 1 2CV HEGA-10 × 3 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.50 Å R-free 0.266 |
| 6H7N ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND PARTIAL AGONIST XAMOTEROL AND NANOBODY Nb6B9 Deposited 2018-07-31 | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain B
44–368（325 aa）
|
Mutation：R68S,M90V,C116L,F327A,F338M,C358A | FVK ~{N}-[2-[[(2~{S})-2-oxidanyl-3-(4-oxidanylphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide × 1 NA SODIUM ION × 1 2CV HEGA-10 × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.50 Å R-free 0.266 |
| 6H7O ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND WEAK PARTIAL AGONIST CYANOPINDOLOL AND NANOBODY Nb6B9 Deposited 2018-07-31 | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain A
44–368（325 aa）
|
Mutation：R68S,M90V,C116L,F327A,F338M,C358A | P32 Cyanopindolol × 1 NA SODIUM ION × 1 2CV HEGA-10 × 5 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.80 Å R-free 0.274 |
| 6H7O ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND WEAK PARTIAL AGONIST CYANOPINDOLOL AND NANOBODY Nb6B9 Deposited 2018-07-31 | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain B
44–368（325 aa）
|
Mutation：R68S,M90V,C116L,F327A,F338M,C358A | P32 Cyanopindolol × 1 NA SODIUM ION × 1 2CV HEGA-10 × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.80 Å R-free 0.274 |
| 6IBL ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND AGONIST FORMOTEROL AND NANOBODY Nb80 Deposited 2018-11-30 | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
44–368（325 aa）
|
Mutation：C32S,C35S,C32S,C35S | H98 ~{N}-[5-[(1~{R})-2-[[(2~{R})-1-(4-methoxyphenyl)propan-2-yl]amino]-1-oxidanyl-ethyl]-2-oxidanyl-phenyl]methanamide × 1 NA SODIUM ION × 1 2CV HEGA-10 × 5 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.70 Å R-free 0.277 |
| 6IBL ACTIVATED TURKEY BETA1 ADRENOCEPTOR WITH BOUND AGONIST FORMOTEROL AND NANOBODY Nb80 Deposited 2018-11-30 | Assembly 2 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain B
44–368（325 aa）
|
Mutation：C32S,C35S,C32S,C35S | H98 ~{N}-[5-[(1~{R})-2-[[(2~{R})-1-(4-methoxyphenyl)propan-2-yl]amino]-1-oxidanyl-ethyl]-2-oxidanyl-phenyl]methanamide × 1 NA SODIUM ION × 1 2CV HEGA-10 × 3 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.1 M Hepes-NaOH pH7.5 and 21-24% PEG1500
|
Resolution 2.70 Å R-free 0.277 |
| 6TKO Phosphorylated turkey beta1 adrenoceptor with bound agonist formoterol coupled to arrestin-2 in lipid nanodisc. Deposited 2019-11-28 | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain A
32–357（326 aa）
|
Mutation：S32G M44C M90V V103C C116L E130W D322K F327A F338M C358A Non-standard monomer：Yes (specific site not provided by mmCIF) | H98 ~{N}-[5-[(1~{R})-2-[[(2~{R})-1-(4-methoxyphenyl)propan-2-yl]amino]-1-oxidanyl-ethyl]-2-oxidanyl-phenyl]methanamide × 1 | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE；Blotted for 2-3 seconds before plunging. Liquid ethane maintained at 92.15 K.
|
Resolution 3.30 Å |